☆ 4.4 Article

Chemotherapy outcomes in EGFR-TKI resistant patients with common and uncommon EGFR mutation: An exploratory retrospective cohort study

THORACIC CANCER (2023)

Related references

Note: Only part of the references are listed.

Review Oncology

Antibody-drug conjugates in lung cancer: dawn of a new era?

Niamh Coleman et al.

Summary: Antibody-drug conjugates (ADCs) are a growing class of oncology drugs that combine cytotoxic chemotherapy with targeted therapy to deliver potent agents to cancer cells. In lung cancer treatment, ADCs have emerged as potential options, with FDA-approved and breakthrough therapy designated ADCs available. Early-phase trials are also exploring novel ADCs for advanced lung cancer. This review discusses the structure, mechanism of action, recent progress, toxicity profiles, and strategies to enhance potency and overcome resistance of ADCs in lung cancer, as well as novel ADC strategies using non-cytotoxic payloads.

NPJ PRECISION ONCOLOGY (2023)

Add to Collection

Article Oncology

Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901)

Yusuke Okuma et al.

Summary: Patients with uncommon EGFR-mutated NSCLC have lower response rates to first-generation EGFR-TKIs. This study aims to evaluate the efficacy of osimertinib in previously untreated NSCLC patients.

FUTURE ONCOLOGY (2022)

Add to Collection

Article Oncology

Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)

Sanjay Popat et al.

Summary: This article presents findings from the UpSwinG study on the efficacy of EGFR TKI treatment in patients with uncommon EGFR mutations. The study shows that in a real-world setting, EGFR TKIs are the preferred treatment option for patients with uncommon EGFR mutations, with strongest outcomes observed in patients with major uncommon and compound mutations.

ONCOLOGIST (2022)

Add to Collection

Article Oncology

Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon EGFR Mutations: A Comparative Cohort Study in China (AFANDA Study)

Hong-Shuai Li et al.

Summary: The study found that dacomitinib demonstrated a more favorable activity with manageable toxicity compared with afatinib in patients with non-small cell lung cancer carrying uncommon EGFR mutations. This study provides further evidence for the application of dacomitinib in this setting.

CANCERS (2022)

Add to Collection

Review Oncology

Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations

Antonio Passaro et al.

Summary: The first-line treatment for NSCLC patients with EGFR mutations is an EGFR TKI, but some patients have uncommon mutations with varying sensitivities to different TKIs, complicating treatment decisions. Recent studies have integrated data on the activity of different TKIs against major uncommon EGFR mutations and proposed treatment strategies for these cases.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Structure-based classification predicts drug response in EGFR-mutant NSCLC

Jacqulyne P. Robichaux et al.

Summary: The study characterized the mutational landscape in 16,715 patients with EGFR-mutant NSCLC and established the structure-function relationship of EGFR mutations on drug sensitivity. EGFR mutations can be separated into four distinct subgroups based on sensitivity and structural changes, predicting patient outcomes following treatment with EGFR inhibitors better than traditional exon-based groups. This structure-based approach delineates functional groups of EGFR mutations that can effectively guide treatment choices and suggest potential improvement in prediction of drug sensitivity to targeted therapies in oncogenes with diverse mutations.

NATURE (2021)

Add to Collection

Review Oncology

Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer

Peter T. Harrison et al.

SEMINARS IN CANCER BIOLOGY (2020)

Add to Collection

Article Oncology

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases

James Chih-Hsin Yang et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

Add to Collection

Article Oncology

Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC

Shuo Yang et al.

LUNG CANCER (2020)

Add to Collection

Article Respiratory System

Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors

Aurelien Brindel et al.

JOURNAL OF THORACIC DISEASE (2020)

Add to Collection

Article Biology

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?

Hyun Ae Jung et al.

BIOLOGY-BASEL (2020)

Add to Collection

Article Oncology

Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy

Haixia Li et al.

LUNG CANCER (2019)

Add to Collection

Article Oncology

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

Chee Khoon Lee et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)

Add to Collection

Article Oncology

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

Chee Khoon Lee et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)

Add to Collection

Article Pathology

Verification of Wild-Type EGFR Status in Non-Small Cell Lung Carcinomas Using a Mutant-Enriched PCR on Selected Cases

Yi-Lin Chen et al.

JOURNAL OF MOLECULAR DIAGNOSTICS (2014)

Add to Collection

Article Oncology

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)

A. Inoue et al.

ANNALS OF ONCOLOGY (2013)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Response Criteria in Oncologic Imaging: Review of Traditional and New Criteria

Temel Tirkes et al.

RADIOGRAPHICS (2013)

Add to Collection

Article Medicine, General & Internal

Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.

Tony S. Mok et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.